Antinuclear Antibody Test Market By Product, By Technique, By Application, By End-use : Global Opportunity Analysis and Industry Forecast, 2021-2031

List of Tables

The global antinuclear antibody test market is envisioned to garner $ 4,999.4million by 2030, growing from $ 1,294.9 million in 2021 at a CAGR of 14.97% from 2022 to 2031.

An anti-nuclear antibody (ANA) test is a blood test performed to find out whether there are any autoantibodies present in the patient showing symptoms of autoimmune diseases. Autoantibodies are usually made by the body against its own cells, present in the serum.

The market expansion of anti-nuclear antibody testing is driven by government healthcare insurance, an increase in autoimmune disorders awareness campaigns, and reimbursement regulations. For instance, the World Lupus Federation (WLF) is an alliance of about 250 lupus organizations from 75 nations across six continents with the goal of helping lupus patients. WLF promotes lupus awareness among the general public and gives lupus patients access to improved medical care facilities like providing assistance in conducting antinuclear antibody tests of the patients.

The individual in charge of doing ANA tests needs to be knowledgeable about both technology and the condition. A person cannot complete the test without comprehending both. The greatest barrier for the global market in the anticipated term is expected to be a lack of skilled staff to operate the testing kits. Additionally, everyone cannot afford the test because of its high cost, which is expected to impede the market's growth throughout the projected time.

Antinuclear antibody testing is anticipated to benefit from the COVID-19 pandemic and experience substantial growth during the pandemic stage. Antinuclear antibody testing has become increasingly popular, which is the main cause of this market growth. These tests demonstrate the existence of autoimmune illnesses in a person's body, making their detection vital. Additionally, the market is developing due to the rising prevalence of autoimmune illnesses in the COVID positive patients. All of these factors support market expansion during the COVID-19 epidemic.

The key players profiled in this report include: Erba Diagnostics, Bio-Rad Laboratories, Inc., Trinity Biotech Plc., Thermo Fisher Scientific, Antibodies Incorporated, EUROIMMUN Medizinische Labordiagnostika AG, Immuno Concepts NA Ltd., Inova Diagnostics, Inc. and ZEUS Scientific, Inc.

Key Benefits For Stakeholders

This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the antinuclear antibody test market analysis from 2021 to 2031 to identify the prevailing antinuclear antibody test market opportunities.
The market research is offered along with information related to key drivers, restraints, and opportunities.
Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
In-depth analysis of the antinuclear antibody test market segmentation assists to determine the prevailing market opportunities.
Major countries in each region are mapped according to their revenue contribution to the global market.
Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
The report includes the analysis of the regional as well as global antinuclear antibody test market trends, key players, market segments, application areas, and market growth strategies.

Key Market Segments

By Product

Reagents Assay Kits
Systems
Software Services

By Technique

ELISA
Immunofluorescence Assay
Multiplex Assay

By Application

Rheumatoid Arthritis
Systemic Lupus Erythematosus
Sjogren's Syndrome
Scleroderma
Others

By End-use

Hospitals
Clinical Laboratories
Physician Office Laboratories
Others

By Region

North America
- U.S.
- Canada
- Mexico
Europe
- Germany
- United Kingdom
- France
- Spain
- Italy
- Rest of Europe
Asia-Pacific
- China
- Japan
- India
- South Korea
- Australia
- Rest Of Asia Pacific
LAMEA
- Brazil
- Saudi Arabia
- UAE
- South Africa
- Rest of LAMEA
Key Market Players
- erba diagnostics mannheim gmbh
- Bio-Rad Laboratories, Inc.
- Trinity Biotech Plc.
- Thermo Fisher Scientific, Inc.
- Antibodies Incorporated
- euroimmun medizinische labordiagnostika ag
- Immuno Concepts NA Ltd.
- Inova Diagnostics, Inc.
- ZEUS Scientific, Inc.

Product Code: A03912

CHAPTER 1:INTRODUCTION

1.1.Report description
1.2.Key market segments
1.3.Key benefits to the stakeholders
1.4.Research Methodology
- 1.4.1.Secondary research
- 1.4.2.Primary research
- 1.4.3.Analyst tools and models

CHAPTER 2:EXECUTIVE SUMMARY

2.1.Key findings of the study
2.2.CXO Perspective

CHAPTER 3:MARKET OVERVIEW

3.1.Market definition and scope
3.2.Key findings
- 3.2.1.Top investment pockets
3.3.Porter's five forces analysis
3.4.Top player positioning
3.5.Market dynamics
- 3.5.1.Drivers
- 3.5.2.Restraints
- 3.5.3.Opportunities
3.6.COVID-19 Impact Analysis on the market
3.7.Regulatory Guidelines
3.8.Value Chain Analysis
3.9.Market Share Analysis
3.10.Key Regulation Analysis
3.11.Patent Landscape

CHAPTER 4: ANTINUCLEAR ANTIBODY TEST MARKET, BY PRODUCT

4.1 Overview
- 4.1.1 Market size and forecast
4.2 Reagents & Assay Kits
- 4.2.1 Key market trends, growth factors and opportunities
- 4.2.2 Market size and forecast, by region
- 4.2.3 Market analysis by country
4.3 Systems
- 4.3.1 Key market trends, growth factors and opportunities
- 4.3.2 Market size and forecast, by region
- 4.3.3 Market analysis by country
4.4 Software & Services
- 4.4.1 Key market trends, growth factors and opportunities
- 4.4.2 Market size and forecast, by region
- 4.4.3 Market analysis by country

CHAPTER 5: ANTINUCLEAR ANTIBODY TEST MARKET, BY TECHNIQUE

5.1 Overview
- 5.1.1 Market size and forecast
5.2 ELISA
- 5.2.1 Key market trends, growth factors and opportunities
- 5.2.2 Market size and forecast, by region
- 5.2.3 Market analysis by country
5.3 Immunofluorescence Assay
- 5.3.1 Key market trends, growth factors and opportunities
- 5.3.2 Market size and forecast, by region
- 5.3.3 Market analysis by country
5.4 Multiplex Assay
- 5.4.1 Key market trends, growth factors and opportunities
- 5.4.2 Market size and forecast, by region
- 5.4.3 Market analysis by country

CHAPTER 6: ANTINUCLEAR ANTIBODY TEST MARKET, BY APPLICATION

6.1 Overview
- 6.1.1 Market size and forecast
6.2 Rheumatoid Arthritis
- 6.2.1 Key market trends, growth factors and opportunities
- 6.2.2 Market size and forecast, by region
- 6.2.3 Market analysis by country
6.3 Systemic Lupus Erythematosus
- 6.3.1 Key market trends, growth factors and opportunities
- 6.3.2 Market size and forecast, by region
- 6.3.3 Market analysis by country
6.4 Sjogren's Syndrome
- 6.4.1 Key market trends, growth factors and opportunities
- 6.4.2 Market size and forecast, by region
- 6.4.3 Market analysis by country
6.5 Scleroderma
- 6.5.1 Key market trends, growth factors and opportunities
- 6.5.2 Market size and forecast, by region
- 6.5.3 Market analysis by country
6.6 Others
- 6.6.1 Key market trends, growth factors and opportunities
- 6.6.2 Market size and forecast, by region
- 6.6.3 Market analysis by country

CHAPTER 7: ANTINUCLEAR ANTIBODY TEST MARKET, BY END-USE

7.1 Overview
- 7.1.1 Market size and forecast
7.2 Hospitals
- 7.2.1 Key market trends, growth factors and opportunities
- 7.2.2 Market size and forecast, by region
- 7.2.3 Market analysis by country
7.3 Clinical Laboratories
- 7.3.1 Key market trends, growth factors and opportunities
- 7.3.2 Market size and forecast, by region
- 7.3.3 Market analysis by country
7.4 Physician Office Laboratories
- 7.4.1 Key market trends, growth factors and opportunities
- 7.4.2 Market size and forecast, by region
- 7.4.3 Market analysis by country
7.5 Others
- 7.5.1 Key market trends, growth factors and opportunities
- 7.5.2 Market size and forecast, by region
- 7.5.3 Market analysis by country

CHAPTER 8: ANTINUCLEAR ANTIBODY TEST MARKET, BY REGION

8.1 Overview
- 8.1.1 Market size and forecast
8.2 North America
- 8.2.1 Key trends and opportunities
- 8.2.2 North America Market size and forecast, by Product
- 8.2.3 North America Market size and forecast, by Technique
- 8.2.4 North America Market size and forecast, by Application
- 8.2.5 North America Market size and forecast, by End-use
- 8.2.6 North America Market size and forecast, by country
  - 8.2.6.1 U.S.
  - 8.2.6.1.1 Market size and forecast, by Product
  - 8.2.6.1.2 Market size and forecast, by Technique
  - 8.2.6.1.3 Market size and forecast, by Application
  - 8.2.6.1.4 Market size and forecast, by End-use
  - 8.2.6.2 Canada
  - 8.2.6.2.1 Market size and forecast, by Product
  - 8.2.6.2.2 Market size and forecast, by Technique
  - 8.2.6.2.3 Market size and forecast, by Application
  - 8.2.6.2.4 Market size and forecast, by End-use
  - 8.2.6.3 Mexico
  - 8.2.6.3.1 Market size and forecast, by Product
  - 8.2.6.3.2 Market size and forecast, by Technique
  - 8.2.6.3.3 Market size and forecast, by Application
  - 8.2.6.3.4 Market size and forecast, by End-use
8.3 Europe
- 8.3.1 Key trends and opportunities
- 8.3.2 Europe Market size and forecast, by Product
- 8.3.3 Europe Market size and forecast, by Technique
- 8.3.4 Europe Market size and forecast, by Application
- 8.3.5 Europe Market size and forecast, by End-use
- 8.3.6 Europe Market size and forecast, by country
  - 8.3.6.1 Germany
  - 8.3.6.1.1 Market size and forecast, by Product
  - 8.3.6.1.2 Market size and forecast, by Technique
  - 8.3.6.1.3 Market size and forecast, by Application
  - 8.3.6.1.4 Market size and forecast, by End-use
  - 8.3.6.2 United Kingdom
  - 8.3.6.2.1 Market size and forecast, by Product
  - 8.3.6.2.2 Market size and forecast, by Technique
  - 8.3.6.2.3 Market size and forecast, by Application
  - 8.3.6.2.4 Market size and forecast, by End-use
  - 8.3.6.3 France
  - 8.3.6.3.1 Market size and forecast, by Product
  - 8.3.6.3.2 Market size and forecast, by Technique
  - 8.3.6.3.3 Market size and forecast, by Application
  - 8.3.6.3.4 Market size and forecast, by End-use
  - 8.3.6.4 Spain
  - 8.3.6.4.1 Market size and forecast, by Product
  - 8.3.6.4.2 Market size and forecast, by Technique
  - 8.3.6.4.3 Market size and forecast, by Application
  - 8.3.6.4.4 Market size and forecast, by End-use
  - 8.3.6.5 Italy
  - 8.3.6.5.1 Market size and forecast, by Product
  - 8.3.6.5.2 Market size and forecast, by Technique
  - 8.3.6.5.3 Market size and forecast, by Application
  - 8.3.6.5.4 Market size and forecast, by End-use
  - 8.3.6.6 Rest of Europe
  - 8.3.6.6.1 Market size and forecast, by Product
  - 8.3.6.6.2 Market size and forecast, by Technique
  - 8.3.6.6.3 Market size and forecast, by Application
  - 8.3.6.6.4 Market size and forecast, by End-use
8.4 Asia-Pacific
- 8.4.1 Key trends and opportunities
- 8.4.2 Asia-Pacific Market size and forecast, by Product
- 8.4.3 Asia-Pacific Market size and forecast, by Technique
- 8.4.4 Asia-Pacific Market size and forecast, by Application
- 8.4.5 Asia-Pacific Market size and forecast, by End-use
- 8.4.6 Asia-Pacific Market size and forecast, by country
  - 8.4.6.1 China
  - 8.4.6.1.1 Market size and forecast, by Product
  - 8.4.6.1.2 Market size and forecast, by Technique
  - 8.4.6.1.3 Market size and forecast, by Application
  - 8.4.6.1.4 Market size and forecast, by End-use
  - 8.4.6.2 Japan
  - 8.4.6.2.1 Market size and forecast, by Product
  - 8.4.6.2.2 Market size and forecast, by Technique
  - 8.4.6.2.3 Market size and forecast, by Application
  - 8.4.6.2.4 Market size and forecast, by End-use
  - 8.4.6.3 India
  - 8.4.6.3.1 Market size and forecast, by Product
  - 8.4.6.3.2 Market size and forecast, by Technique
  - 8.4.6.3.3 Market size and forecast, by Application
  - 8.4.6.3.4 Market size and forecast, by End-use
  - 8.4.6.4 South Korea
  - 8.4.6.4.1 Market size and forecast, by Product
  - 8.4.6.4.2 Market size and forecast, by Technique
  - 8.4.6.4.3 Market size and forecast, by Application
  - 8.4.6.4.4 Market size and forecast, by End-use
  - 8.4.6.5 Australia
  - 8.4.6.5.1 Market size and forecast, by Product
  - 8.4.6.5.2 Market size and forecast, by Technique
  - 8.4.6.5.3 Market size and forecast, by Application
  - 8.4.6.5.4 Market size and forecast, by End-use
  - 8.4.6.6 Rest Of Asia Pacific
  - 8.4.6.6.1 Market size and forecast, by Product
  - 8.4.6.6.2 Market size and forecast, by Technique
  - 8.4.6.6.3 Market size and forecast, by Application
  - 8.4.6.6.4 Market size and forecast, by End-use
8.5 LAMEA
- 8.5.1 Key trends and opportunities
- 8.5.2 LAMEA Market size and forecast, by Product
- 8.5.3 LAMEA Market size and forecast, by Technique
- 8.5.4 LAMEA Market size and forecast, by Application
- 8.5.5 LAMEA Market size and forecast, by End-use
- 8.5.6 LAMEA Market size and forecast, by country
  - 8.5.6.1 Brazil
  - 8.5.6.1.1 Market size and forecast, by Product
  - 8.5.6.1.2 Market size and forecast, by Technique
  - 8.5.6.1.3 Market size and forecast, by Application
  - 8.5.6.1.4 Market size and forecast, by End-use
  - 8.5.6.2 Saudi Arabia
  - 8.5.6.2.1 Market size and forecast, by Product
  - 8.5.6.2.2 Market size and forecast, by Technique
  - 8.5.6.2.3 Market size and forecast, by Application
  - 8.5.6.2.4 Market size and forecast, by End-use
  - 8.5.6.3 UAE
  - 8.5.6.3.1 Market size and forecast, by Product
  - 8.5.6.3.2 Market size and forecast, by Technique
  - 8.5.6.3.3 Market size and forecast, by Application
  - 8.5.6.3.4 Market size and forecast, by End-use
  - 8.5.6.4 South Africa
  - 8.5.6.4.1 Market size and forecast, by Product
  - 8.5.6.4.2 Market size and forecast, by Technique
  - 8.5.6.4.3 Market size and forecast, by Application
  - 8.5.6.4.4 Market size and forecast, by End-use
  - 8.5.6.5 Rest of LAMEA
  - 8.5.6.5.1 Market size and forecast, by Product
  - 8.5.6.5.2 Market size and forecast, by Technique
  - 8.5.6.5.3 Market size and forecast, by Application
  - 8.5.6.5.4 Market size and forecast, by End-use

CHAPTER 9: COMPANY LANDSCAPE

9.1. Introduction
9.2. Top winning strategies
9.3. Product Mapping of Top 10 Player
9.4. Competitive Dashboard
9.5. Competitive Heatmap
9.6. Key developments

CHAPTER 10: COMPANY PROFILES

10.1 erba diagnostics mannheim gmbh
- 10.1.1 Company overview
- 10.1.2 Company snapshot
- 10.1.3 Operating business segments
- 10.1.4 Product portfolio
- 10.1.5 Business performance
- 10.1.6 Key strategic moves and developments
10.2 Bio-Rad Laboratories, Inc.
- 10.2.1 Company overview
- 10.2.2 Company snapshot
- 10.2.3 Operating business segments
- 10.2.4 Product portfolio
- 10.2.5 Business performance
- 10.2.6 Key strategic moves and developments
10.3 Trinity Biotech Plc.
- 10.3.1 Company overview
- 10.3.2 Company snapshot
- 10.3.3 Operating business segments
- 10.3.4 Product portfolio
- 10.3.5 Business performance
- 10.3.6 Key strategic moves and developments
10.4 Thermo Fisher Scientific, Inc.
- 10.4.1 Company overview
- 10.4.2 Company snapshot
- 10.4.3 Operating business segments
- 10.4.4 Product portfolio
- 10.4.5 Business performance
- 10.4.6 Key strategic moves and developments
10.5 Antibodies Incorporated
- 10.5.1 Company overview
- 10.5.2 Company snapshot
- 10.5.3 Operating business segments
- 10.5.4 Product portfolio
- 10.5.5 Business performance
- 10.5.6 Key strategic moves and developments
10.6 euroimmun medizinische labordiagnostika ag
- 10.6.1 Company overview
- 10.6.2 Company snapshot
- 10.6.3 Operating business segments
- 10.6.4 Product portfolio
- 10.6.5 Business performance
- 10.6.6 Key strategic moves and developments
10.7 Immuno Concepts NA Ltd.
- 10.7.1 Company overview
- 10.7.2 Company snapshot
- 10.7.3 Operating business segments
- 10.7.4 Product portfolio
- 10.7.5 Business performance
- 10.7.6 Key strategic moves and developments
10.8 Inova Diagnostics, Inc.
- 10.8.1 Company overview
- 10.8.2 Company snapshot
- 10.8.3 Operating business segments
- 10.8.4 Product portfolio
- 10.8.5 Business performance
- 10.8.6 Key strategic moves and developments
10.9 ZEUS Scientific, Inc.
- 10.9.1 Company overview
- 10.9.2 Company snapshot
- 10.9.3 Operating business segments
- 10.9.4 Product portfolio
- 10.9.5 Business performance
- 10.9.6 Key strategic moves and developments